Device Trial Radar · NCT04970212
Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures
Last checked: Nov 20, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
65
Actual
Start
Sep 24, 2021
Primary completion
Oct 8, 2022
Study completion Oct 8, 2022
Sponsor
- Lead sponsor
- Techsomed Medical Technologies LTDNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 21, 2021
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Clinical study planned to demonstrate that the BioTraceIO Lite, available post-procedure, is effective at estimating the area of tissue damage as measured on 24-hour post-procedure (T=24hrs) CECT scan and that it is safe, based on an assessment of device-related Adverse Events. Multi-center (up to 6 investigational sites) prospective single-arm clinical investigation 50 evaluable subjects total stratified by cancer type (primary hepatocellular carcinoma vs. secondary liver metastases).
Conditions
- Carcinoma, Hepatocellular
- Metastatic Liver Cancer
Interventions
BioTraceIO LiteDevice
The BioTraceIO software will analyze the ultrasound images, and provide the physician with an estimated tissue damage map.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety - Adverse EventsTime frame: 1 year
- Effectiveness - DICETime frame: 1 year
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic
Phoenix, Arizona
Stanford Medicine
Stanford, California
Massachusetts General Hospital
Boston, Massachusetts
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.